ASIRI HOSPITAL HOLDINGS PLC

INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDED

30th September 2025

Asiri Hospital Holdings PLC and Its Subsidiaries

STATEMENT OF PROFIT OR LOSS
For the Period Ended 30 September

	GROUP		COMPANY	
	30-Sep-25	**30-Sep-24**	**30-Sep-25**	**30-Sep-24**
	Rs.	**Rs.**	**Rs.**	**Rs.**
	Un-audited	**Un-audited**	**Un-audited**	**Un-audited**
Revenue	**17,240,460,935**	15,010,154,252	**7,848,994,841**	6,418,146,824
Cost of Services	**(8,591,094,824)**	(8,112,207,938)	**(3,636,863,554)**	(3,288,988,979)
Gross Profit	**8,649,366,111**	6,897,946,314	**4,212,131,287**	3,129,157,845
Other Income	**144,386,603**	184,892,666	**79,407,469**	1,525,646,061
Administrative Expenses	**(4,593,210,050)**	(3,979,048,986)	**(1,882,728,478)**	(1,595,381,927)
Selling and Distribution Expenses	**(470,692,088)**	(428,319,944)	**(255,923,338)**	(224,352,803)
Finance Costs	**(1,014,698,667)**	(992,605,680)	**(790,281,715)**	(799,131,730)
Finance Income	**409,948,259**	490,974,558	**110,889,742**	52,608,939
Profit/(Loss) Before Tax	**3,125,100,168**	2,173,838,928	**1,473,494,966**	2,088,546,384
Tax Expense	**(798,681,112)**	(969,446,870)	**(286,341,479)**	(257,000,000)
Profit/(Loss) for the Period	**2,326,419,056**	1,204,392,058	**1,187,153,487**	1,831,546,384
Attributable to:				
Equity Holders of the Parent Company	**2,177,325,041**	1,073,290,037		
Non-Controlling Interest	**149,094,015**	131,102,021		
	2,326,419,056	1,204,392,058		
Earnings Per Share- Basic	**1.91**	0.94	**1.04**	1.61
Dividend Per Share- Ordinary Shares	**0.00**	1.50	**0.00**	1.50

STATEMENT OF COMPREHENSIVE INCOME

For the Period Ended 30 September

	Group		Company	
	30-Sep-25	**30-Sep-24**	**30-Sep-25**	**30-Sep-24**
	Rs.	**Rs.**	**Rs.**	**Rs.**
	Un-audited	**Un-audited**	**Un-audited**	**Un-audited**
Profit for the Period	**2,326,419,056**	1,204,392,058	**1,187,153,487**	1,831,546,384
Other Comprehensive Income not to be reclassified to Statement of Profit or Loss in subsequent periods (net of tax):				
Net Other Comprehensive Income not to be reclassified to Statement of Profit or Loss in subsequent periods (net of tax):	-	-	-	-
Other Comprehensive Income/(Loss) for the Period, Net of Tax	-	-	-	-
Total Comprehensive Income/(Loss) for the Period, Net of Tax	**2,326,419,056**	**1,204,392,058**	**1,187,153,487**	1,831,546,384
Total Comprehensive Income Attributable to:				
Equity Holders of the Parent Company	**2,177,325,041**	1,073,290,037		
Non-Controlling Interest	**149,094,015**	131,102,021		
	2,326,419,056	1,204,392,058		

Asiri Hospital Holdings PLC and Its Subsidiaries

STATEMENT OF PROFIT OR LOSS

For the Three Months Ended 30 September

	GROUP		COMPANY	
	30-Sep-25	**30-Sep-24**	**30-Sep-25**	**30-Sep-24**
	Rs.	**Rs.**	**Rs.**	**Rs.**
	Un-audited	**Un-audited**	**Un-audited**	**Un-audited**
Revenue	**8,520,190,303**	7,758,759,081	**3,915,054,716**	3,260,145,613
Cost of Services	**(4,309,471,843)**	(4,148,347,391)	**(1,819,461,368)**	(1,647,878,117)
Gross Profit	**4,210,718,460**	3,610,411,690	**2,095,593,348**	1,612,267,496
Other Income	**68,159,409**	61,431,276	**35,678,975**	1,490,488,411
Administrative Expenses	**(2,346,905,222)**	(2,054,277,841)	**(973,795,715)**	(804,866,066)
Selling and Distribution Expenses	**(238,038,693)**	(228,251,795)	**(130,832,141)**	(116,254,907)
Finance Costs	**(522,068,314)**	(484,630,630)	**(404,723,473)**	(390,580,475)
Finance Income	**203,427,438**	225,673,516	**55,260,683**	26,431,897
Profit Before Tax	**1,375,293,078**	1,130,356,216	**677,181,677**	1,817,486,356
Tax Expense	**(275,180,733)**	(647,779,996)	**(56,214,491)**	(165,000,000)
Profit for the Period	**1,100,112,345**	482,576,220	**620,967,187**	1,652,486,356
Attributable to:				
Equity Holders of the Parent Company	**1,018,989,936**	416,184,923		
Non-Controlling Interests	**81,122,409**	66,391,297		
	1,100,112,345	482,576,220		
Earnings Per Share - Basic	**0.90**	0.37	**0.55**	1.45
Dividend Per Share - Ordinary Shares	**0.00**	1.50	**0.00**	1.50

STATEMENT OF COMPREHENSIVE INCOME

For the Three Months Ended 30 September

	Group		Company	
	30-Sep-25	**30-Sep-24**	**30-Sep-25**	**30-Sep-24**
	Rs.	**Rs.**	**Rs.**	**Rs.**
	Un-audited	**Un-audited**	**Un-audited**	**Un-audited**
Profit / (Loss) for the Period	**1,100,112,345**	482,576,220	**620,967,187**	1,652,486,356
Other Comprehensive Income not to be reclassified to Statement of Profit or Loss in subsequent periods (net of tax):				
Net Other Comprehensive Income not to be reclassified to Statement of Profit or Loss in subsequent periods (net of tax):	-	-	-	-
Other Comprehensive Income/(Loss) for the Period, Net of Tax	-	-	-	-
Total Comprehensive Income/(Loss) for the Period, Net of Tax	**1,100,112,345**	482,576,220	**620,967,187**	1,652,486,356
Attributable to:				
Equity Holders of the Parent Company	**1,018,989,936**	416,198,009		
Non-Controlling Interests	**81,122,409**	66,378,211		
	1,100,112,345	482,576,220		

Asiri Hospital Holdings PLC and Its Subsidiaries

STATEMENT OF FINANCIAL POSITION

GROUP 31-Mar-25 Rs. Un-audited	COMPANY 31-Mar-25 Rs. Un-audited		GROUP 30-Sep-25 Rs. Un-audited	GROUP 30-Sep-24 Rs. Un-audited	COMPANY 30-Sep-25 Rs. Un-audited	COMPANY 30-Sep-24 Rs. Un-audited
		ASSETS				
		Non-current Assets				
35,261,736,339	14,971,249,009	Property, Plant and Equipment	**35,011,911,910**	33,565,613,256	**14,767,410,484**	14,289,358,258
1,239,255,846	974,416,666	Right of Use Assets	**1,275,872,743**	1,236,631,013	**992,113,307**	961,235,886
609,654,071	-	Goodwill	**609,654,071**	609,654,071	**-**	-
-	41,413,042,529	Investment in Subsidiaries	-	-	**41,413,070,184**	12,345,794,784
7,193,473,966	20,060,242	Loans granted to Related Parties	**7,442,640,344**	3,886,978,634	**-**	-
70,409,812	44,427,812	Other Non Current Assets	**75,040,643**	70,487,564	**49,058,643**	44,505,564
57,200,837	57,200,837	Other Non-Current Financial Assets	**57,200,837**	30,000,000	**57,200,837**	30,000,000
44,431,730,871	**57,480,397,095**		**44,472,320,550**	39,399,364,538	**57,278,853,456**	27,670,894,492
		Current Assets				
974,246,361	464,971,134	Inventories	**1,213,611,912**	1,226,359,757	**544,067,171**	555,406,338
2,024,541,810	2,124,360,551	Trade and Other Receivables	**2,441,388,806**	1,371,343,820	**2,953,080,771**	1,696,657,725
1,272,976,210	1,483,771,765	Loans Granted to Related Parties	**1,317,069,353**	7,872,369,090	**1,749,950,415**	382,378,395
5,436,222,728	2,008,341,810	Other Current Assets	**8,222,646,594**	3,653,451,853	**2,574,557,455**	780,807,313
654,099,154	166,359,209	Cash and Cash Equivalents	**791,417,544**	1,216,442,658	**198,742,188**	162,721,483
10,362,086,264	**6,247,804,470**		**13,986,134,209**	15,339,967,177	**8,020,398,001**	3,577,971,254
54,793,817,135	**63,728,201,565**	**Total Assets**	**58,458,454,759**	54,739,331,716	**65,299,251,456**	31,248,865,747
		EQUITY AND LIABILITIES				
		Capital and Reserves				
4,748,108,334	4,748,108,334	Stated Capital	**4,748,108,334**	4,748,108,334	**4,748,108,334**	4,748,108,334
11,856,358,164	27,624,699,191	Other Components of Equity	**11,710,995,075**	9,674,000,443	**27,624,699,191**	3,943,767,585
3,135,441,695	1,624,827,004	Retained Earnings	**5,458,129,823**	6,641,312,631	**2,811,980,491**	1,334,741,708
19,739,908,194	**33,997,634,528**	**Share Holders' Fund**	**21,917,233,231**	21,063,421,408	**35,184,788,016**	10,026,617,627
1,789,272,495	-	Non-Controlling Interests	**1,938,366,513**	1,822,898,493	**-**	-
21,529,180,689	**33,997,634,528**	**Total Equity**	**23,855,599,744**	22,886,319,901	**35,184,788,016**	10,026,617,627
		Non-current Liabilities				
5,861,868,272	8,070,619,239	Interest Bearing Loans and Borrowings	**3,545,493,557**	3,443,158,476	**6,012,115,496**	4,579,475,363
5,602,692,680	8,719,827,008	Deferred Tax Liabilities	**6,197,731,321**	5,043,668,271	**9,317,239,116**	2,302,588,122
868,652,333	361,069,127	Employee Benefit Liability	**883,688,607**	818,072,906	**354,426,168**	316,931,466
12,333,213,284	**17,151,515,374**		**10,626,913,485**	9,304,899,653	**15,683,780,780**	7,198,994,951
		Current Liabilities				
5,818,959,544	2,565,281,723	Trade and Other Payables	**6,518,497,070**	4,202,555,824	**2,204,936,658**	1,335,662,230
75,761,221	61,359,499	Dividend Payable	**92,760,502**	1,810,683,138	**78,447,677**	1,767,636,002
9,231,683,345	6,692,344,448	Interest Bearing Loans and Borrowings	**10,978,271,550**	10,027,909,329	**8,820,743,003**	7,747,793,376
1,529,095,312	316,564,446	Income Tax Payable	**1,726,112,262**	1,381,745,762	**422,337,800**	182,000,000
4,275,923,740	2,943,501,547	Bank Overdraft	**4,660,300,146**	5,125,218,109	**2,904,217,523**	2,990,161,561
20,931,423,162	**12,579,051,663**		**23,975,941,530**	22,548,112,162	**14,430,682,661**	14,023,253,169
54,793,817,135	**63,728,201,565**	**Total Equity and Liabilities**	**58,458,454,759**	54,739,331,716	**65,299,251,456**	31,248,865,747
17.35	29.89	Net Assets Per Share	19.27	18.52	30.93	8.81

The above figures are provisional & subject to audit.
It is certified that the Financial Statements have been prepared in accordance with the requirements of the Companies Act No.7 of 2007.

-sgd-
.....
S.L.R.Piyal
Director Finance

The Board of Directors is responsible for the preparation and presentation of these Financial Statements.
Signed for and on behalf of the Board.

-sgd-
.....
Ashok Pathirage
Chairman / Managing Director

-sgd-
.....
Haresh Kaimal
Director

14 November 2025
Colombo

STATEMENT OF CHANGES IN EQUITY

For the Period Ended 30 September

GROUP

	Equity Attributable to Equity Holders of the Parent							
	Stated Capital	**Revaluation Reserve**	**Reserve on Consolidation**	**Retained Earnings**	**Fair Value Reserve of Financial Assets at FVOCI**	**Foreign Currency Translation Reserve**	**Minority Interest**	**Total**
	Rs.	**Rs.**	**Rs.**	**Rs.**	**Rs.**	**Rs.**	**Rs.**	**Rs.**
Balance as at 01 April 2024	**4,748,108,334**	**10,592,574,929**	**(919,511,357)**	**7,376,200,859**	**(101,877,871)**	**823,404**	**1,736,127,637**	**23,432,445,935**
Profit for the Period	-	-	-	1,073,290,037	-	-	131,102,021	1,204,392,058
Other Comprehensive Income	-		-	-	-	-	-	-
Total Comprehensive Income	**-**	**-**	**-**	**1,073,290,037**	**-**	**-**	**131,102,021**	**1,204,392,058**
Equity Investments at FVOCI reclassified to Retained Earnings				(101,877,871)	101,877,871			
Acquisition of Non-Controlling Interest	-	-	-	-	-	-	-	-
Interim Dividends 2024/25				(1,706,300,394)				(1,706,300,394)
Subsidiaries Dividend to Minority Share Holders							(43,808,658)	(43,808,658)
Acquisition of Non-Controlling Interest			113,467				(522,507)	(409,040)
Balance as at 30 September 2024	**4,748,108,334**	**10,592,574,929**	**(919,397,890)**	**6,641,312,631**	**-**	**823,404**	**1,822,898,493**	**22,886,319,901**
Balance as at 01 April 2025	**4,748,108,334**	**11,693,431,117**	**(919,502,000)**	**4,200,306,782**	**19,040,586**	**(1,476,628)**	**1,789,272,498**	**21,529,180,689**
Profit for the Period	-	-	-	2,177,325,041	-	-	149,094,015	2,326,419,056
Other Comprehensive Income	-	-	-	-	-	-	-	-
Total Comprehensive Income	**-**	**-**	**-**	**2,177,325,041**	**-**	**-**	**149,094,015**	**2,326,419,056**
Acquisition of Non-Controlling Interest	-	-	-		-	-	-	-
Balance as at 30 September 2025	**4,748,108,334**	**11,693,431,117**	**(919,502,000)**	**6,377,631,823**	**19,040,586**	**(1,476,628)**	**1,938,366,513**	**23,855,599,744**

COMPANY

	Stated Capital	**Revaluation Reserve**	**Fair Value Reserve of Financial Assets at FVOCI**	**Retained Earnings**	**Total**
	Rs.	**Rs.**	**Rs.**	**Rs.**	**Rs.**
Balance as at 01 April 2024	**4,748,108,334**	**3,943,767,585**	**-**	**1,209,495,716**	**9,901,371,635**
Loss for the Period	-	-	-	1,831,546,384	1,831,546,384
Other Comprehensive Income	-	-	-	-	-
Total Comprehensive Income	-	-	-	1,831,546,384	1,831,546,384
Interim Dividends 2024/25			-	(1,706,300,394)	(1,706,300,394)
Balance as at 30 September 2024	**4,748,108,334**	**3,943,767,585**	**-**	**1,334,741,707**	**10,026,617,627**
Balance as at 01 April 2025	**4,748,108,334**	**4,502,387,362**	**23,122,311,829**	**1,624,827,003**	**33,997,634,528**
Profit for the Period	-	-	-	1,187,153,487	1,187,153,487
Other Comprehensive Income	-	-	-	-	-
Total Comprehensive Income	-	-	-	1,187,153,487	1,187,153,487
Equity Investments at FVOCI reclassified to Retained Earnings					-
Balance as at 30 September 2025	**4,748,108,334**	**4,502,387,362**	**23,122,311,829**	**2,811,980,491**	**35,184,788,016**

Asiri Hospital Holdings PLC and Its Subsidiaries

STATEMENT OF CASH FLOWS

For the Period Ended 30 September

	GROUP		COMPANY	
	30-Sep-25 Rs. Un-audited	**30-Sep-24 Rs. Un-audited**	**30-Sep-25 Rs. Un-audited**	**30-Sep-24 Rs. Un-audited**
Cash Flows from/(used in) Operating Activities				
Profit Before Tax Expense	3,125,100,168	2,173,838,928	**1,473,494,966**	**2,088,546,384**
Adjustments for				
Depreciation	915,928,036	893,247,744	387,818,621	382,295,812
Amortization of Leasehold Assets	104,116,379	87,910,913	69,008,379	61,133,708
Loss/(Profit) on Disposal of Property, Plant and Equipment	(493,990)	434,491	-	-
Loss/(Gain) on share disposal	-	(12,615,325)	-	-
Script Dividend Income	-	(14,442,348)	-	-
Provision for Bad and Doubtful Debts	27,736,641	16,832,974	6,803,039	6,614,741
Provision for Retirement Gratuity	109,900,922	92,139,541	43,833,679	39,608,378
Unrealized Foreign Currency Exchange Gain	5,824,037	(1,864,826)	3,637,384	(267,385)
Finance Costs	1,014,698,667	992,605,680	790,281,715	799,131,730
Income from Investments	(409,948,259)	(490,974,558)	(110,889,742)	(52,608,939)
Operating Profit Before Working Capital Changes	**4,892,862,602**	3,737,113,214	**2,663,988,041**	3,324,454,429
Changes in Working Capital				
(Increase)/Decrease in Inventories	(239,365,551)	55,682,130	(79,096,037)	11,101,195
(Increase)/ Decrease in Other Current Assets	(2,394,066,468)	(1,736,789,350)	(473,217,613)	(159,163,826)
(Increase)/ Decrease in Trade and Other Receivables	(393,741,185)	(246,148,510)	(826,548,013)	(651,690,593)
(Decrease)/Increase in Trade and Other Payables	794,442,265	(1,335,147)	(298,346,377)	(276,587,548)
Cash Generated from Operations	**2,660,131,663**	1,808,522,338	**986,780,002**	2,248,113,658
Income Tax paid	(434,145,275)	(349,432,096)	(10,000,000)	(10,000,000)
Finance Costs paid	(743,075,790)	(923,672,655)	(366,070,739)	(588,901,736)
Defined Benefit Plan Costs paid	(94,490,511)	(59,228,216)	(50,476,638)	(32,164,391)
Net Cash from Operating Activities	**1,388,420,086**	476,189,371	**560,232,624**	1,617,047,531
Cash Flows from/(used in) Investing Activities				
Acquisition of Property, Plant and Equipment	(668,575,324)	(527,848,439)	(185,585,320)	(223,466,826)
Acquisition of Right of use assets	(1,464,894)	-	(1,464,894)	-
Increase in Interest in Subsidiaries	-	-	(27,655)	(438,800)
Proceed from/(repayment of) Loans Obtained From Related Parties	120,000,000	-	-	(1,344,317,103)
Cash received from Sale of shares	-	287,012,765	-	-
Proceeds from Disposal of Property, Plant and Equipment	2,965,305	1,915,834	1,605,164	1,913,515
Income From Investments	2,069,323	67,732,589	382,946	430,906
Net Cash used in Investing Activities	**(545,005,590)**	(171,187,250)	**(185,089,758)**	(1,565,878,310)
Cash Flows from/(used in) Financing Activities				
Dividends Paid to Minority Shareholders	-	(10,232,316)	-	-
Reversal of unclaimed dividends	16,999,281	-	16,999,281	-
Acquisition of Non Controlling Interests	(27,655)	(438,800)	-	-
Net Proceeds/(Net Repayments) from External Borrowings	(979,084,372)	(814,979,779)	(232,909,007)	(141,215,920)
Repayment of Lease Obligations	(128,359,766)	(110,768,273)	(87,566,141)	(79,847,982)
Net Cash used in Financing Activities	**(1,090,472,511)**	(936,419,168)	**(303,475,867)**	(221,063,902)
Net Increase/(Decrease) in Cash and Cash Equivalents	**(247,058,015)**	(631,417,047)	**71,666,999**	(169,894,680)
Cash and Cash Equivalents at the Beginning of the Year	(3,621,824,586)	(3,277,358,404)	(2,777,142,338)	(2,657,545,401)
Cash and Cash Equivalents at the End of the Year	**(3,868,882,602)**	(3,908,775,451)	**(2,705,475,335)**	(2,827,440,078)
Analysis of Cash and Cash Equivalents				
Favourable Balances				
Cash in Hand and at Bank	791,417,544	1,216,442,658	198,742,188	162,721,483
Unfavourable Balances				
Bank Overdrafts	(4,660,300,146)	(5,125,218,109)	(2,904,217,523)	(2,990,161,561)
Cash and Cash Equivalents	**(3,868,882,602)**	(3,908,775,451)	**(2,705,475,335)**	(2,827,440,078)

NOTES TO THE INTERIM FINANCIAL STATEMENTS
For the Period Ended 30 September 2025

1. Corporate Information
1.1 General
Asiri Hospital Holdings PLC ("Company") is a public limited liability Company, incorporated and domiciled in Sri Lanka and listed on the Colombo Stock Exchange. The registered office and principal place of business is located at No. 181, Kirula Road, Colombo 5.

1.2 Date of Authorisation for Issue
The Interim Condensed Financial Statements of the Group and the Company for the period ended 30 September 2025 were authorised for issue by the Board of Directors on 14 November 2025.

2. Basis of Preparation
The Interim Condensed Financial Statements have been prepared in accordance with Sri Lanka Accounting Standard - LKAS 34 Interim Financial Reporting. These interim condensed financial statements should be read in conjunction with the annual financial statements for the year ended 31 March 2024. These financial statements provide the information as required in terms of Rule 7.4 of the Colombo Stock Exchange.

3. Accounting Policies
The same accounting policies and methods of computation as stated in the annual financial statements for the year ended 31 March 2024 are followed in the preparation of these Interim Condensed Financial Statements.

4. Other Information

4.1 Loans Granted to Related Parties

Group

This includes loans granted to Softlogic Holdings PLC, Softlogic Brands (Pvt) Ltd ,Softlogic Super market (Pvt) Ltd, Softlogic Retail (Pvt) Ltd, Softlogic Communication Services (Pvt) Ltd and interest receivable thereon. The interest is charged at prevailing market interest rates for these loans.

Company
This includes loans granted to Softlogic Holdings PLC, Softlogic Brands (Pvt) Ltd and Softlogic Super Market (Pvt) Ltd and interest receivable thereon. The interest is charged at prevailing market interest rates for these loans.

4.2 Contingent Liabilities
A dispute has arisen with the Department of Inland Revenue with regard to the applicability of the income tax exemption for the years of assessment 2005/06 to 2014/15, in terms of the agreement entered between Asiri Surgical Hospital PLC and the Board of Investment of Sri Lanka (BOI) in year 2000. With respect to the same we have received written notifications from the Tax Appeal Commission so far for the years of assessments 2005/06 to 2013/14 and the company is assessing the provisioning requirement based on the applicable tax laws during the period. We are also in the process of initiating legal action against these assessments in the Court of Appeal.

We also have a case in the Court of Appeal in CA (Writ) 386/ 2016 preventing the recoverability of tax for the same mater and this will be coming up for argument in January 2026, Since there is a litigation, in accordance with Paragraph 92 of LKAS 37, we are unable to provide further information on this and associated risks, in order not to impair the outcome and/or prejudice the Company's position in this matter Other than above, there are no significant changes in the nature of the contingent liabilities and contingent assets which were disclosed in the Annual Report for the year ended 31 March 2024.

4.3 Capital Expenditure Commitments
There were no material commitments outstanding as at 30 September 2025 for future capital expenditure except for below;
Rs.21,901,554 contracted with suppliers for the construction of Asiri Hospital Kandy (Rs.21,901,554 as at 30 September 2024).

4.4 Comparative Information
Where necessary comparative figures have been reclassified to conform with the current year's presentation.

4.5 Events Occurring After the Reporting Period
There were no material events that occurred after the reporting date that require adjustments or disclosure to the Financial Statements.

INVESTOR INFORMATION

Market Value of Shares

The market value of an ordinary share of Asiri Hospital Holdings PLC is as follows:

	Quarter to 30-Sep-25	Quarter to 30-Sep-24
Highest Price per Share (Rs.)	41.00	25.40
Lowest Price per Share (Rs.)	31.00	21.90
Last Traded Price per Share (Rs.)	36.80	22.80

No of Shares Representing Stated Capital	As at 30-Sep-25	As at 30-Sep-24
No of Ordinary Shares	1,137,533,596	1,137,533,596

* Earnings and net assets per share are based on 1,137,533,596 shares in issue as at 30 September 2025.

Statement of Shareholding of Directors Name of Director	As at 30-Sep-25	As at 30-Sep-24
Mr. A. K. Pathirage	371,664	371,664
Mr. Rajaratnam Selvaskadan	-	-
Mr. H K Kaimal	-	-
Mr. Vishal Bali	-	-
Mr. A. N. Thadani	-	-
Mr. Govinda Waduge Don Hemantha Udaya Gunawardena	-	-
Mr. Saar Shapira	-	-
Mr. I. M. Furkan	-	-

Major Shareholdings Twenty Largest Shareholders	As at 30-Sep-25	%	As at 30-Sep-24	%
Softlogic Holdings Plc	627,025,050	55.12	627,025,050	55.12
Merrill Lynch Pierce Fenner & Smith-Tpg Growth Iii Sf Pte Ltd	328,258,328	28.86	328,258,328	28.86
Bbh-Tundra Sustainable Frontier Fund	30,000,000	2.64	30,000,000	2.64
Softlogic Life Insurance Plc-A/C No. 04 (Participating Fund)	9,000,000	0.79	9,000,000	0.79
Sri Lanka Insurance Corporation Ltd-Life Fund	7,851,792	0.69	7,851,792	0.69
J.B. Cocoshell (Pvt) Ltd	7,488,264	0.66	1,834,229	0.16
Mr. Pujitha Punsiri Subasinghe	7,385,340	0.65	7,588,922	0.67
Softlogic Life Insurance Plc-A/C No. 05 (Non-Participating Fund)	5,956,877	0.52	5,956,877	0.52
Deutsche Bank Ag As Trustee For Jb Vantage Value Equity Fund	5,090,006	0.45	-	-
Employees Trust Fund Board	4,245,693	0.37	4,245,693	0.37
Jafferjee Brothers Exports (Private)Limited	3,487,500	0.31	-	-
Dr. Welagedara Mudiyanselage Swarnamali Welagedara	3,375,000	0.30	3,375,000	0.30
Mr. Hewa Komanage Jayantha Dharmadasa	2,908,650	0.26	2,788,920	0.25
Sampath Bank PLC/Yaden Capital (Private) Limited	2,905,812	0.26	-	-
Dr. Luhubanduwaduge Don Abo Claudius Luvis	2,557,423	0.22	2,741,720	0.24
Mr. Mohamed Faizer Hashim	2,087,160	0.18	2,087,160	0.18
Miss Theja Thushari Weerasinghe	1,746,630	0.15	1,746,630	0.15
Sri Lanka Insurance Corporation Ltd-General Fund	1,557,417	0.14	2,807,417	0.25
Mr. Uditha Harilal Palihakkara	1,436,255	0.13	1,386,369	0.12
Miss. Wasala Mudiyanse Ranuki Kiyama Weerasinghe	-	-	2,343,750	0.21
Mrs. Wasala Mudiyanse Saseni Abilasha Weerasinghe	-	-	2,343,750	0.21
Mr. Ahamed Umar Maniku	-	-	3,219,350	0.28
Mrs. Samaradiwakara Chandrasekara Karunanayake Wasala Kumarasinghe Mudiyanse Ralahamillage Nilanthi Kumudu Kumari Bandara	-	-	4,687,500	0.41
	1,054,363,197	92.69	1,051,288,457	92.42
Shares held by the Balance Shareholdings	83,170,399	7.31	86,245,139	7.58
Total Issued Shares	1,137,533,596	100.00	1,137,533,596	100.00
Public Shareholding	166,921,677	14.67	166,912,603	14.67
Total Number of Public Shareholders	5,761		5,850	

The Float- adjusted market capitalization as at 30th September 2025 is Rs. 6,153,601,740.92 and the Company is in compliance with option 3 of the CSE Listing Rules 7.13.1 (i) (a) which requires 7.5 % minimum public holding percentage and 500 minimum public shareholders

CORPORATE INFORMATION

Name of the Company
Asiri Hospital Holdings PLC

Registered Office
181, Kirula Road, Colombo 05,
Sri Lanka.

Office & Administrative Complex
Asiri Surgical Hospital PLC
21, Kirimandala Mawatha,
Colombo 05, Sri Lanka.
Telephone: 011 4524400
Email: info@asiri.lk
Web: www.asirihealth.com

Company Registration Number
PQ204

Legal Form
A quoted public company incorporated in Sri Lanka on 29 September 1980, under the Companies Act No.17 of 1982, with limited liability.Re-registered on 30 September 2008 under the Companies Act No. 07 of 2007.

Stock Exchange Listing
The Ordinary Shares of the Company have been listed with the Colombo Stock Exchange since June 1986.

Board of Directors
Mr. A. K. Pathirage - Chairman/Managing Director
Mr. G. W.D.H. U. Gunawardena (Appointed w.e.f 7th January 2025)
Mr. Rajaratnam Selvaskandan
Mr. H K Kaimal
Mr.V. Bali
Mr. A. N. Thadani
Mr. S. Shapira (Appointed w.e.f 14th February 2025)
Mr. M.I. Furkan (Appointed w.e.f 21st April 2025)
Mr. G.D.K.L.D. Silva (Appointed w.e.f 2nd July 2025)

Audit Committee
Chairman
Mr. M.I. Furkan (Appointed w.e.f 21st April 2025)
Independent Non- Executive Director

Committee Members
Mr. G.D.K.L.D. Silva (Appointed w.e.f 2nd July 2025)
Independent Non-Executive Director

Mr. H K Kaimal
Non Independent Non-Executive Director

Frequency of Meetings
Committee meets quarterly

Nomination and Governance Committee
Chairman
Mr. M.I. Furkan (Appointed w.e.f 21st April 2025)
Independent Non- Executive Director

Committee Members
Mr. G.D.K.L.D. Silva (Appointed w.e.f 2nd July 2025)
Independent Non-Executive Director

Mr.V. Bali
Independent Non-Executive Director

Frequency of Meetings
Committee meets once a year

Related Party Transactions Review Committee
Chairman
Mr. M.I. Furkan (Appointed w.e.f 21st April 2025)
Independent Non- Executive Director

Committee Members
Mr. G.D.K.L.D. Silva (Appointed w.e.f 2nd July 2025)
Independent Non-Executive Director

Mr. H K Kaimal
Non Independent Non-Executive Director

Frequency of Meetings
Committee meets at least once a quarter

Subsidiary Companies
Central Hospital Ltd
114, Norris Canal Road, Colombo 10.

Asiri Central Hospitals Ltd
114, Norris Canal Road, Colombo 10.
Asiri Surgical Hospital PLC
21, Kirimandala Mawatha, Colombo 5.

Asiri Diagnostics Services (Pvt) Ltd
181, Kirula Road, Colombo 05.

Asiri Hospital Matara (Pvt) Ltd
26, Esplanade Road, Uyanwatte,
Matara.

Asiri Laboratories (Pvt) Ltd
181, Kirula Road, Colombo 5.

Asiri Hospital Galle (Pvt) Ltd
10, Wackwella Road, Galle.

Asiri AOI Cancer Centre (Pvt) Ltd
21, Kirimandala Mawatha, Colombo 5.

Asiri Port City Hospital (Pvt) Ltd.
14, De Fonseka Place, Colombo 5.

Asiri Academy of Health Sciences (Pvt) Ltd.
181, Kirula Road, Colombo 5.

Asiri Diagnostics Services (Asia) Pte Limited
8, Temasek Boulevard, # 35-03 Suntec Tower 3.
Singapore.

Auditors
Messrs. Ernst & Young
(Chartered Accountants)
109, Galle Road,
Colombo 03.

Secretaries
Messrs. Softlogic Corporate Services (Pvt) Ltd
14, De Fonseka Place, Colombo 5.

Stock Code
ASIR.N0000

Bankers
Commercial Bank of Ceylon PLC
Sampath Bank PLC
Nations Trust Bank PLC
Hatton National Bank PLC
Cargills Bank Limited
Bank of Ceylon PLC
National Development Bank PLC
Seylan Bank PLC
DFCC Bank PLC